With expertise in development and CMC in short supply globally, CDMO choice is absolutely critical for sponsors relying on them to accelerate development pathway, says Pharmatech Associates.
Ahead of November’s CPhI Worldwide event in Frankfurt, Germany, BioProcess Insider hosted a LinkedIn Live discussion with Bikash Chatterjee and Stephanie Gaulding, the respective CEO and MD at drug development consultancy firm Pharmatech Associates about current outsourcing strategies and how to go about selecting a CDMO partner.
Listen to the full discussion, as part of the BioProcess Insider Expression Platform, below, or at Spotify, Apple, or wherever you get your podcasts.
About the Author
Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.
You May Also Like